studies

HEPATOLOGY, VOLUME 62, NUMBER 1 (SUPPL) AASLD ABSTRACTS 1207A
Disclosures:
Nowlan Selvapatt - Speaking and Teaching: Gilead, BMS
Ashley S. Brown - Advisory Committees or Review Panels: MSD, Roche, Bristol-Myers-Squibb,
Gilead, Janssen, Abbvie, Achillion; Speaking and Teaching:
MSD, Roche, Bristol-Myers Squibb, Gilead, Janssen, Abbvie
The following authors have nothing to disclose: Bilal Khan, Abbesega Ananthavarathan
2048
A Multicenter, Prospective, Observational, Non-interventional
Cohort Study in Chinese Subjects with HBeAg
Negative Chronic Hepatitis B Receiving Therapy with
Peginterferon alfa: An Interim Analysis
Xinyue Chen 1 , Qianguo Mao 2 , Hui Li 3 , Xu Li 4 , Yuqin Xu 5 , Yao
Xie 6 , Yingxia Liu 7 , Weiping Zhu 8 , Xiaoguang Dou 9 , Fusheng
Zhu 10 , Huanwei Zheng 11 , Shuqin Zhang 12 , Mingxiang Zhang 13 ,
Yongfeng Yang 14 , Yaoren Hu 15 , Chuanwu Zhu 16 , Jiguang Ding 17 ,
Youwen Tan 18 , Qing Xie 21 , Jifang Sheng 19 , Zhiliang Gao 20 , Yi
Xie 21 , Hong Ren 22 , Jidong Jia 23 ; 1 Beijing YouAn Hospital, Capital
Medical University, Beijing, China; 2 Xiamen Hospital of Traditional
Chinese Medicine, Xiamen, China; 3 The Third People’s
Hospital of KunMing City, Kunming, China; 4 The First Affiliated
Hospital of Anhui Medical University, Hefei, China; 5 The 211
Hospital of People’s Liberation Army, Haerbin, China; 6 Beijing
Ditan Hospital, Capital Medical University, Beijing, China; 7 Shenzhen
Third People’s Hospital, Shenzhen, China; 8 QingDao Infectious
Diseases Hospital, Qingdao, China; 9 Shengjing Hospital of
China Medical University, Shenyang, China; 10 General Hospital
of Dagang Oilfield, Tianjin, China; 11 The Fifth Hospital of Shijiazhuang,
Shijiazhuang, China; 12 Hepatology Hospital of Jilin
Province, Changchun, China; 13 The Sixth People’s Hospital of
Shenyang, Shenyang, China; 14 The Second Hospital of Nanjing,
Nanjing, China; 15 Ningbo No. 2 Hospital, Ningbo, China; 16 The
Fifth People’s Hospital of Suzhou, Suzhou, China; 17 Ruian People’s
Hospital, Ruian, China; 18 The Third People’s hospital of Zhenjiang,
Zhenjiang, China; 19 The First Affiliated Hospital of Zhejing
University, Hangzhou, China; 20 The Third Affiliated Hospital, Sun
Yat-sen University, Guangzhou, China; 21 Shanghai Roche Pharmaceuticals
Ltds., Shanghai, China; 22 The Second Affiliated Hospital
of Chongqing Medical University, Chongqing, China; 23 Beijing
Friendship Hospital, Capital Medical University, Beijing, China
Objectives: To evaluate the efficacy and safety of Peginterferon
alfa (Peg-IFNα) in Chinese patients with HBeAg negative
chronic hepatitis B (CHB) in routine clinical practice. Methods:
Chinese adult HBeAg negative CHB patients, not co-infected
with HIV, HAV, or HCV, not on concomitant telbivudine therapy,
and treated with Peg-IFNα (dosing in accordance with
approved SmPC in China and as per Chinese standard clinical
practice) were included in a prospective, multicenter, observational,
non-interventional cohort study. An interim analysis
of efficacy and safety of Peg-IFNα was performed for the first
50% patients at 48 weeks on-treatment (end of standard treatment).
Results: The study included 503 patients (80.7% of male)
with mean age of 37.5 years, 2.84 log IU/mL mean baseline
HBsAg and 5.27 log IU/mL mean baseline HBV-DNA. Of
these, 411 patients (81.7%) completed the 48-week treatment.
Response rate of HBV-DNA suppression (HBV-DNA